Company HedgePath Pharmaceuticals Inc
Equities
US42278K1025
Biotechnology & Medical Research
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Frank O'Donnell
CEO | Chief Executive Officer | 74 | 13/22/13 |
James McNulty
DFI | Director of Finance/CFO | 73 | 13/22/13 |
Amy M. McCord
LAW | General Counsel | - | 01/19/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Frank O'Donnell
CEO | Chief Executive Officer | 74 | 13/22/13 |
Samuel Sears
BRD | Director/Board Member | 80 | 02/13/02 |
Ronald Osman
BRD | Director/Board Member | 78 | 23/23/23 |
Niraj Vasisht
BRD | Director/Board Member | 61 | 13/22/13 |
Michelle Yanez
BRD | Director/Board Member | 52 | 13/22/13 |
Michael Jerman
BRD | Director/Board Member | 40 | 24/23/24 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 172,023,545 | 71,400,692 ( 41.51 %) | 0 | 41.51 % |
Company contact information
Inhibitor Therapeutics, Inc.
449 South 12th Street Unit 1705
33602, Tampa
+813 864 2562
http://www.inhibitortx.comSector
1st Jan change | Capi. | |
---|---|---|
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |